INTRODUCTION
In t he mo der n world, obesity becomes a real problem, generating multiple pathological conditions. The association of diabetes mellitus (DM) with obesity is often found in the general population, especially in adults and in elderly people. Also, the prevalence of metabolic syndrome is increasing in Western countries, while the age of its onset is decreasing [1] .
In patients with obesity, DM and metabolic syndrome, fatty infiltration of the liver is quite frequent [2] . It was thought in the past that the liver fatty changes were a consequence of insulin resistance that occurred in patients with DM and obesity, a conclusion also supported by contemporary studies [3] , but new data has emerged that suggest that steatosis precedes type 2 DM and metabolic syndrome in a large number of cases [4, 5] , leading to the conclusion that there is a bi-directional, causal link between NAFLD and DM [6, 7] .
Among patients with nonalcoholic fatty liver disease (NAFLD), a percentage will develop nonalcoholic steatohepatitis (NASH), which can progress to liver cirrhosis. The factors determining why some of the patients with liver steatosis J Gastrointestin Liver Dis, June 2016 Vol. 25 No 2: 167-174 progress to NASH, with further development of fibrosis and cirrhosis, are not entirely known.
In the latter years, the etiological spectrum of liver cirrhosis (LC) has being modified. The discovery of potent drugs that cure chronic hepatitis C virus (HCV) infection or control viral replication in chronic hepatitis B virus (HBV) patients has decreased the proportion of viral etiologies. Considering the high prevalence of DM, estimated to reach 7.7% in the world by 2030 [8] , and the high prevalence of NAFLD in diabetics, estimated to reach almost 60% [9] , NAFLD will be one of the most important problems to confront hepatologists as a leading cause of LC. In such patients, the risk of hepatocellular carcinoma is still present, estimated to be as high as 0.3%/year in NASH patients [10] , so that early diagnosis and staging are important for screening strategies.
Evaluation of patients with NAFLD can be performed by biologic tests and by ultrasound (to quantify the amount of fat in the liver), but severity of the disease (i.e. quantification of inflammation and fibrosis) is usually assessed by liver biopsy. But considering that the rate of obesity could exceed 30% in the Western world, this huge number of liver biopsies could be a problem. On the other hand, from the point of view of the patient, he or she could be reticent to an invasive procedure [11] , especially when multiple non-invasive modalities of liver disease evaluation are in use.
Inflammation plays an important role in differentiating between simple steatosis and the more severe steatohepatitis [12] , but finally the prognosis is given by the severity of fibrosis. Starting from this point, many researchers have focused on liver fibrosis assessment using noninvasive methods (FibroMax, NAFLD score or elastographic methods); their usefulness is already agreed upon by international consensus [13] .
The last 10 years have had a crucial role in liver fibrosis assessment using elastographic methods. These techniques use ultrasound waves to stimulate the liver tissue and thus assess liver elasticity or stiffness as a marker of fibrosis. Starting with Transient Elastography (TE) [14] [15] [16] and continuing with Acoustic Radiation Force Impulse techniques (ARFI) [17] and Two Dimensional Shear Waves Elastography (2D-SWE) [18] , all these methods have demonstrated good results in the assessment of liver fibrosis not only in chronic viral liver diseases, but also in fatty liver disease.
Since type 2 diabetic patients are very often overweight and obese and in many cases have increased levels of serum triglycerides while all three factors are considered to be risk factors for significant and severe fibrosis, the aim of our study was to evaluate a population of diabetic patients regarding the severity of liver steatosis using ultrasound (US) and of liver fibrosis using a non-invasive method -TE.
METHODS

Patients
The study group included type 2 diabetic patients referred to the Metabolic Diseases Outpatient Department of a tertiary referral center from Timisoara, Romania. They were prospectively randomized, every first 5 patients who presented for consultation during a day, so that 392 type 2 diabetic patients were selected, and evaluated in the same session by means of transabdominal US and liver elastography (TE, FibroScan, EchoSens). The enrolment period was of 6 months (January to June 2013). Inclusion criteria were: patients with type 2 DM, older than 18 years, who agreed to participate in the study. Exclusion criteria were: pregnant women, patients with implanted pace-makers, patients with focal liver lesions detected by US, patients who refused blood sampling or elastographic measurements, patients with significant alcohol intake (more than 20 g/day).
In these patients, the following parameters were documented: body mass index (BMI), waist circumference, year of diabetes onset, serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), gammaglutamyl transpeptidase (GGT), alkaline phosphatase (AP), triglycerides, HbA1c, HBsAg, anti HCV Ab, the presence of hypertension, DM therapy, alcohol consumption habits, as well as the liver aspect on US examination and liver stiffness (LS) measurements by means of TE.
We used a historical group of previously evaluated 152 controls: 109 healthy volunteers (medical students, nurses and medical doctors from our hospital, none of them having a history of liver disease, acute or chronic) and 43 hospitalized patients with no history of liver disease, normal values of aminotransferases and normal liver at US [19] . None of them had a severe disease such as congestive heart failure, renal failure, or diabetes. This control group included 87 (57.2%) women and 65 (42.8%) men, mean age 45.3±17.6 years, ranging from 18 to 87 years.
All patients agreed to participate in this study; the study was approved by the local Ethics Committee and was in accordance with the Helsinki Declaration of 1975.
Ultrasound examination
The severity of the fat amount in the liver was evaluated by US in fasting patients, with a Siemens Accuson S2000 ultrasound system (Siemens AG, Erlangen, Germany) using a convex 4CI transducer. A semi-quantitative scale was used, according to the subjective assessment of the "brightness" of the liver as compared to the renal parenchyma and the intensity of "posterior attenuation". The scale ranged from 0 to 3: S0: no steatosis (no posterior attenuation) (Fig.1) ; S1: mild steatosis (discrete posterior attenuation) (Fig. 2) ; S2: moderate steatosis (obvious attenuation) (Fig. 3) ; S3: severe steatosis (intense posterior attenuation which makes impossible to visualize the diaphragm) (Fig. 4) . The US examination was performed by four expert ultrasonographists (level III according to the EFSUMB classification, www.efsumb.org).
Transient Elastography
Liver stiffness was evaluated in all patients by TE, using a FibroScan® device (EchoSens, Paris, France). The measurements were performed in the right liver lobe, through the intercostal spaces, with the patient in a dorsal decubitus position with the right arm in maximal abduction. All measurements were performed in fasting conditions. Reliable LS measurements were defined as the median value of 10 LS measurements with a success rate ≥60% and an interquartile range <30%. Liver stiffness was expressed in kPa. When valid measurements could not be obtained with the M probe, the XL probe was used. Transient elastography measurements were made by four experienced operators, with more than 500 TE evaluations each. For a good differentiation between stages of liver fibrosis we used the following LS cut-off values, proposed by Wong in 2010 [16] : F2-F3 7-10.2kPa; F4 ≥ 10.3 kPa, considering that these two points in evolution are important (F2-F3 for quite a severe disease and F=4 for the possible complications and the need for follow-up).
Statistical analysis
The statistical analysis was performed using the SPSS software, Version 20.0 (IBM SPSS Statistics) and Microsoft Office Excel 2007. The Kolmogorov-Smirnov test was used for testing the distribution of numerical variables. Mean value and standard deviation were calculated for numerical variables with normal distribution, while in cases of nonnormal distribution, median values and range intervals were used. Qualitative variables were presented as numbers and percentages. Parametric tests (t-test) were used for the assessment of differences between numerical variables with normal distribution; and nonparametric tests (Mann-Whitney or Kruskal-Wallis tests) for variables with non-normal distribution. Multivariate analysis was performed using logistic regressions. Chi-square (χ 2 ) test (with Yates' correction for continuity) was used to compare proportions expressed as percentages ("n" designates the total number of patients included in a particular subgroup). 95% confidence intervals were calculated for each predictive test and a p-value < 0.05 was considered as significant for each statistic test.
RESULTS
The patients' characteristics are presented in Table I . Reliable LS measurements by means of TE were obtained in 298/392 patients (76%), patients who were included in the final analysis. Out of these 298 patients, 260 (87.2%) had steatosis by US: S1: 98 patients (32.9%), S2: 118 patients (39.6%), S3: 44 patients (14.8%) ( Table II) .
The mean LS value in the study group was 7.7±6.5 kPa. According to the US-evaluated steatosis subgroups, the LS values were: S0: 5.1±1.3 kPa; S1: 6.6±4.6 kPa, S2: 8.1±6.8 kPa; S3: 8.6±5.6 kPa.
By using the proposed cut-off values [16] in our cohort of 298 patients, significant fibrosis (F2-F3: 7-10.2 kPa) was encountered in 18.8% (56/298) patients diagnosed with NAFLD by means of US, while 13.8% (41/298) patients had LS values suggestive of cirrhosis (F4 ≥10.3 kPa) (Table II) . Liver stiffness values higher than 10.3 kPa, suggestive for cirrhosis were significantly more frequently found in patients with moderate and severe steatosis (S3+S4) than in patients with absent or mild steatosis (S0+S1): 11.5% vs. 2.6%, p=0.0005. There were no significant differences with regard to LS values suggestive of significant fibrosis (F2, F3) in patients with moderate and severe steatosis (S3+S4) vs. patients with steatosis absent or mild (S0+S1): 12.1% vs. 8%, p=0.13.
In patients with LS values suggestive of cirrhosis there was a significant difference between patients with mild steatosis and moderate steatosis (S1 vs. S2 p=0.01) and between patients with moderate and severe steatosis (S2 vs. S3, p=0.009)
We then evaluated whether the association of type 2 DM and obesity in NAFLD patients increased the risk of fibrosis. In the univariant analysis, steatosis, obesity, hypertriglyceridemia, and ALT were associated with LS values higher than 7 kPa, suggestive for the presence of liver fibrosis, while age was not associated with LS ≥7 kPa (Table III) .
We conducted an additional multivariate logistic regression analysis including possible risk factors for LS values higher than 7 kPa, thus suggestive for the presence of liver fibrosis, in order to find out which of the parameters had an independent association with fibrosis. Obesity, steatosis, higher ALT, hypertriglyceridemia were independently associated with LS values >7 kPa, suggestive for the presence of liver fibrosis. In contrast, gender, age, GGT, FA, waist circumference did not prove to be risk factors (Table IV) . 4720 subjects, US was found to be 84.8% sensitive and 93.6% specific to detect moderate and severe steatosis as compared with liver histology, with an AUROC of 0.93 [20] . This metaanalysis argues for using US to screen for liver steatosis in daily practice, besides being an inexpensive and widely available method. The accuracy of US is high enough to be confident to proceed to further steps of evaluation, especially in cases with significant (at least moderate) steatosis, since US alone cannot discriminate between simple steatosis and fibrosis or inflammation/ballooning, which are the histologic features of NASH. An alternative to the subjective US evaluation of liver steatosis (for which some US experience is required) is the Controlled Attenuation Parameter (CAP), a noninvasive tool used for grading hepatic steatosis, available in the newer models of FibroScan®. CAP measures the intensity of US attenuation due to hepatic fat. Results are expressed as dB/m, ranging between 100-400 dB/m [21] .
Thus, if steatosis is found in a diabetic patient, liver function tests should be performed. In patients suspected to have NASH (increased ALT with no other causes, such as chronic infection with HBV or HCV, excessive alcohol consumption, autoimmune hepatitis, etc) a liver biopsy can be proposed. But considering the high prevalence of DM in the Western world, this "morphological" strategy can be very difficult to implement. Alternatives to liver biopsy can be the elastographic evaluation of the liver or biological tests such as FibroMax. Ultrasound based elastography and especially TE are increasingly used for liver fibrosis assessment.
Transient elastography was first introduced in practice for LS estimation in patients with HCV chronic infection, but later also for HBV chronic infection, or in NAFLD patients. Considering the reliability of TE for liver fibrosis assessment, especially in patients with advanced fibrosis (significant, severe fibrosis and cirrhosis), this method can be a good tool for population screening in some disorders such as metabolic diseases or chronic alcohol abuse. If patients with alcohol abuse are more difficult to convince to undergo such an evaluation, patients with DM, who have frequent medical appointments, can be more easily screened for chronic liver disease.
In our type 2 DM patients (87.3% of them with at least mild steatosis), significant fibrosis was found using TE in 18.8% of cases, while 13.8% of patients had LS values suggestive of cirrhosis (F4 >10.3 kPa); thus, 32.6% of diabetic patients included in our study could have more severe liver involvement. We tried to exclude excessive alcohol consumption in our group by history taking. Despite a negative history, probably some of the patients drink more than the damaging quantity of alcohol, thus increasing their risk for significant liver fibrosis. On the other hand, 6.3% of these patients had also chronic viral hepatitis, which also increases the risk for liver fibrosis. Even if we exclude the patients with chronic viral hepatitis, there still remains a large number of diabetic patients having significant fibrosis.
As compared with the controls, the mean LS values were significantly higher in the whole group, and in the different groups according to US steatosis degrees. But there were no significant differences between the control group and the patients without steatosis (S0). The fact that the control group In the control group [19] , reliable LS measurements were obtained in 144 (94.7%) subjects, mean value 4.8±1.3 kPa, ranging from 2.3 to 8.8 kPa. In this group we did not find significant differences between the mean LS value in obese subjects (12 patients with BMI>30kg/m2) vs. subjects with BMI <30kg/m 2 : 5.3±1.6 kPa, vs. 4.8±1.2 kPa, p=0.32. There were no significant differences between the study group and the control group regarding gender distribution (p=0.36), however patients in the control group were significantly younger than those in the study group (45.3±17.6 years vs. 61±7.8 years , p < 0.0001).
DISCUSSION
Diabetes mellitus is nowadays a real problem in the Western world, with an increasing prevalence in daily practice. In association with obesity and hypertriglyceridemia, DM can severely affect the liver, with development of NAFLD. As already mentioned, recent studies have concluded that there is a bi-directional, causal link between NAFLD and DM [6, 7] .
Passing from chronic viral hepatites (which can be now treated with great success) to metabolic liver diseases, the hepatologist is now faced with this new reality. Diabetologists have to screen diabetic patients in regard to micro and macrovascular involvement, since these complications affect the patients' life expectancy and quality of life. Beside cardiovascular disease, it is more and more obvious that the liver has become a target organ that needs to be explored in these patients. With the increasing prevalence of obesity and sedentary life style in the Western world, more and more frequently diabetic patients are found to have elevated liver enzymes (AST/ALT), while ultrasound examination of the liver reveals, in many cases, different degrees of steatosis.
Since in many cases steatosis is the first step in developing NASH, we decided to establish how often liver steatosis is present in our type 2 DM patients and to what extent. We found out that the vast majority (87.3%) had steatosis, in 54.2% of cases moderate or severe. More than half of the diabetic patients included in our study had high triglyceride levels, another factor favoring steatosis. We evaluated the presence and severity of steatosis by US alone since, according to published data, this seems to be accurate enough in daily practice. In a meta-analysis that included 49 studies with J Gastrointestin Liver Dis, June 2016 Vol. 25 No 2: 167-174 and the study group were not age-matched might not have changed the results; several studies have shown that age does not influence LS [19, 22] . Similarly, the fact that presence of obesity did not influence the mean LS values in controls represents an argument for using US and TE to screen diabetic patients for liver involvement.
Regarding severity of liver fibrosis assessed using TE, the limit of 7 kPa proposed for significant fibrosis [16] might be too low. In a European study, a higher cut-off was proposed for significant fibrosis (> 8 kPa) [23] . In that study, using 8 kPa to predict significant fibrosis in diabetic patients with steatosis, significant fibrosis was found in 17.2% of them. If we use this cut-off value (> 8 kPa) in our cohort, the proportion of patients with significant fibrosis will become 23.8% (71/298). If we exclude the patients with chronic viral hepatitis from this group, we obtain a prevalence of significant fibrosis similar to that in the Dutch patients' group [34] .
Both studies reveal that increased LS is present in diabetic patients. Definitely, many of them have co-morbidities, such as obesity, steatosis, hypertriglyceridemia, even without taking into consideration their actual alcohol consumption. Patients at risk for significant liver fibrosis can be identified by liver function tests. Increased aminotransferase levels suggest the presence of inflammation (NASH), which must be then confirmed by other means. In our cohort, about 18% of subjects had increased ALT levels. Searching for viral hepatitis in such patients is mandatory. Some studies suggest that the prevalence of HCV infection in diabetic patients is higher than in the general population; others did not find this association [24] .
Transabdominal US examination of the liver is easy to perform in diabetic patients, and when moderate or severe steatosis is found, the suspicion of significant fibrosis increases [23] . In our patients with LS >7 kPa, suggestive for significant fibrosis and in those with LS >10.3 kPa, suggestive of cirrhosis, the severity of steatosis assessed by US was higher. On the other hand, we also found LS values suggestive for significant or severe fibrosis in patients with no or mild steatosis, thus raising the question if LS evaluation must be performed only in diabetic patients with significant steatosis on US, or in all diabetic patients.
In type 2 DM patients we found that fibrosis was correlated with obesity, steatosis (NAFLD), hypertriglyceridemia and increased aminotransferases (OR >2). Thus, by evaluating these parameters in diabetic patients we can find the patients at high risk for significant or severe fibrosis. Gender and age seem to have no role in increasing the severity of LS.
Transient elastography can be a good tool to screen for fibrosis, since it is available in many centers, it is noninvasive, repetitive, not very expensive and performed in less than 5 minutes. But some drawbacks must be considered, maybe the most important is the method's feasibility: valid measurements are possible using the M probe only in 85% of cases [25] or less [26] . Using both the M and XL probes, up to 93% of patients can be screened [27] . In our diabetic patients, the feasibility of TE was only 76.7% despite using both probes, probably because it is difficult to evaluate these patients, most of them being overweight and obese (89.6%).
The TE cut-off values proposed by different authors to diagnose various stages of fibrosis (significant fibrosis, severe fibrosis and cirrhosis) vary. For significant fibrosis (F≥2), 7kPa [16] [32] . For alcoholic steatohepatitis (ASH) the proposed cut-off value for cirrhosis is 22.4 kPa [33] , and for chronic cholestatic diseases it is 17.3 kPa [34] .
The cut-off value for LC proposed by Wong et al. (>10.3 kPa) [16] seems to be very low, thus increasing the prevalence of LC in this cohort of diabetic patients. In a study performed by Lupşor et al. in NASH patients, using liver biopsy as the reference method, the cut-off value to predict at least F3 was 10.4 kPa (AUROC=0.978) [15] . Thus, finding cut-off values to delimitate contiguous stages of fibrosis can be difficult. But values higher than 10.3 kPa are suggestive of severe fibrosis in most studies.
As an alternative to TE, other US-based elastographic methods (point SWE or 2D SWE) are ready to be used for LS assessment in clinical practice [35] [36] [37] . What are their advantages? The elastographic module is implemented in a standard US machine, so that elastography can be performed immediately after the US evaluation of the liver for steatosis, without moving the patient to another machine. The feasibility of ARFI elastography is very high, about 98% [38] . The same good feasibility was observed for 2D SWE technology [18] . The cut-off values differ according to the elastographic method and the US machine used, as well as according to the etiology of hepatitis, so that the cut off values must be known by the practitioners.
A limitation of our study is that liver biopsy or other noninvasive modalities for fibrosis estimation (such as FibroTest or FibroMax) were not available for confirming the severity of liver fibrosis. Another limitation is the possible overlapping with other liver disorders. But we believe that the aim of this study was fulfilled. We found that in our cohort of type 2 DM patients, 85% had liver steatosis on US examination and we could estimate by using a noninvasive technique that more than 30% of them could have at least significant liver fibrosis. Considering all of the above, LS assessment in type 2 DM patients should become common practice, especially in obese patients, in those with liver steatosis, with increased ALT levels or hypertriglyceridemia. The upper LS limit of normal by TE can be discussed, but values higher than 7 or 8 kPa are usually relevant for significant liver injury. In patients with LS values suggestive for at least significant liver injury, another non-invasive test such as FibroMax or liver biopsy could be proposed for a definite diagnosis and prognosis assessment.
CONCLUSIONS
Liver steatosis diagnosed by US occurs frequently in type 2 DM patients. More than half of these patients have moderate or severe steatosis as assessed by US. A significant increase in liver stiffness can be found in more than 30% of these patients. Liver stiffness assessment in type 2 diabetic patients should be performed systematically in order to identify those with significant fibrosis.
